Conference item icon

Conference item

Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.

Abstract:

mTOR inhibitors avoid calcineurin nephrotoxicity, but sirolimus de novo is associated with unacceptable side effects and higher rejection rates. We have investigated a modified strategy: alemtuzumab induction with tacrolimus and mycophenolate maintenance, switching from tacrolimus to sirolimus at 6 months and stopping mycophenolate at 12 months. Here, we report the 6-year follow-up of 30 patients prospectively recruited to this single-arm pilot study and compare outcomes to a matched contempo...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1111/ajt.12572

Authors


Expand authors...
Volume:
14
Issue:
3
Pages:
677-684
Host title:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Publication date:
2014-03-01
Event location:
United States
DOI:
EISSN:
1600-6143
ISSN:
1600-6135
Source identifiers:
145531

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP